Overview

Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation

Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
Interventional, randomized, double-blind, placebo-controlled study encompassing 2 development phases (Phase 2 and Phase 3).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Kiniksa Pharmaceuticals, Ltd.
Treatments:
Mavrilimumab